Pedro Cotta Abrahão Reis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pedro Cotta Abrahão Reis has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
João Evangelista Ponte Conrado
Universidade Federal do Ceará (UFC), CE, Brazil
3 shared publicationsJoão Pedro Oliveira
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
3 shared publications- Ellen R. Blanchard-Cavagis
Université Paris Cité, Paris, France
2 shared publications - Erick Figueiredo Saldanha
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Department of Medicine, University of Toronto, Toronto, ON, Canada; Harvard T. H. Chan School, Harvard University, Boston, MA
2 shared publications Mariana Macambira Noronha
Universidade Federal do Ceará, Fortaleza, Brazil
2 shared publications- Mariana Macambira Noronha
Department of Medical Sciences, Universidade Federal do Ceará, CE, Brazil
2 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103145
Mammography screening in women aged 39–49 years: Updated randomized evidence and implications for screening policy
- 23 June 2026
- Published by Elsevier in Cancer Epidemiology
- Vol. 103, 103145
Open AccessMammography screening in women aged 39–49 years: Updated randomized evidence and implications for screening policy
- Open Access
- 12 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (2)
Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis
Purpose: Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa) improves outcomes in premenopausal women with hormone receptor–positive (HR +) breast cancer (BC), most commonly using monthly administration. The potential equivalence of 3-monthly (3 M) versus monthly (1 M) schedules has been suggested but remains uncertain. Methods: We performed a systematic review and meta-analysis of interventional studies comparing 3 M and 1 M GnRHa regimens in premenopausal women with HR + BC receiving endocrine therapy. Outcomes included ovarian escape (OE), mean estradiol (E2) levels, disease-free survival (DFS), progression-free survival (PFS), and adverse events. Subgroup analyses were performed by estradiol assay type, and a sensitivity analysis restricted to RCTs. Results: Fifteen studies comprising 4,324 patients were included, of whom 2,098 (48%) received a 3 M regimen. The pooled OE was 10% and showed no significant difference between schedules (RR 0.86; 95% CI 0.60–1.22; p = 0.39). Ultrasensitive assays yielded higher OE detection (31%) without inter-regimen differences (RR 0.90; 95% CI 0.38–2.14). Mean E2 concentrations at 12 weeks were similar (MD 1.36 pg/mL; 95% CI –3.66 to 6.38), with consistent findings in RCT-only analyses (MD –1.77 pg/mL; 95% CI –5.71 to 2.17). DFS (RR 1.02; 95% CI 0.67–1.56) and PFS (RR 0.86; 95% CI 0.72–1.04) were also comparable. No clinically relevant differences were observed in reported safety outcomes. Conclusion: 3 M GnRHa achieved OFS efficacy comparable to 1 M regimens, with no meaningful differences in survival or safety. The findings support 3 M GnRHa as a valid and practical alternative for OFS in appropriately selected premenopausal women with HR + BC.
- 12 June 2026
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 217 (2)
Open AccessThree-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis
Purpose: Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa) improves outcomes in premenopausal women with hormone receptor–positive (HR +) breast cancer (BC), most commonly using monthly administration. The potential equivalence of 3-monthly (3 M) versus monthly (1 M) schedules has been suggested but remains uncertain. Methods: We performed a systematic review and meta-analysis of interventional studies comparing 3 M and 1 M GnRHa regimens in premenopausal women with HR + BC receiving endocrine therapy. Outcomes included ovarian escape (OE), mean estradiol (E2) levels, disease-free survival (DFS), progression-free survival (PFS), and adverse events. Subgroup analyses were performed by estradiol assay type, and a sensitivity analysis restricted to RCTs. Results: Fifteen studies comprising 4,324 patients were included, of whom 2,098 (48%) received a 3 M regimen. The pooled OE was 10% and showed no significant difference between schedules (RR 0.86; 95% CI 0.60–1.22; p = 0.39). Ultrasensitive assays yielded higher OE detection (31%) without inter-regimen differences (RR 0.90; 95% CI 0.38–2.14). Mean E2 concentrations at 12 weeks were similar (MD 1.36 pg/mL; 95% CI –3.66 to 6.38), with consistent findings in RCT-only analyses (MD –1.77 pg/mL; 95% CI –5.71 to 2.17). DFS (RR 1.02; 95% CI 0.67–1.56) and PFS (RR 0.86; 95% CI 0.72–1.04) were also comparable. No clinically relevant differences were observed in reported safety outcomes. Conclusion: 3 M GnRHa achieved OFS efficacy comparable to 1 M regimens, with no meaningful differences in survival or safety. The findings support 3 M GnRHa as a valid and practical alternative for OFS in appropriately selected premenopausal women with HR + BC.
- Open Access
- 5 May 2026
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 147, 103146
Circulating tumor DNA for predicting recurrence and mortality in patients with resected Melanoma: A systematic review and meta-analysis
- 5 May 2026
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 147, 103146
Open AccessCirculating tumor DNA for predicting recurrence and mortality in patients with resected Melanoma: A systematic review and meta-analysis
- Open Access
- 30 January 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 220, 105167
Adjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials
- 30 January 2026
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 220, 105167
Open AccessAdjuvant aspirin and Cyclooxygenase-2 inhibitors in resected, PIK3CA-mutated colorectal cancer: A systematic review and meta-analysis of randomized controlled trials
- Open Access
- 13 August 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (5) , e70047
Prognostic and Predictive Value of ctDNA for Metastatic Uveal Melanoma: A Systematic Review and Meta‐Analysis
Metastatic uveal melanoma (mUM) is a rare disease associated with poor prognosis and limited therapeutic options. Recent studies showed that detecting ctDNA is feasible and can aid treatment decisions for patients with mUM. We systematically searched PubMed, EMBASE, and Cochrane databases for eligible studies published up to May 2025 that included patients with mUM and reported data on the association between ctDNA and survival outcomes (OS and PFS). Statistical analyses were performed using Review Manager 5.4 software. Of the initial 450 records, seven studies met eligibility, including 518 patients with mUM. At baseline, ctDNA positivity was associated with significantly worse PFS (HR 2.34; 95% CI 1.56–3.51; p < 0.01; I2 = 0%) and OS (HR 3.32; 95% CI 2.09–5.29; p < 0.01; I2 = 48%). In patients treated with tebentafusp, ctDNA clearance was associated with superior OS (HR 0.19; 95% CI 0.07–0.49; p < 0.01; I2 = 46%) and any decrease in ctDNA was associated with better OS (HR 0.42; 95% CI 0.22–0.80; p < 0.01; I2 = 0%). This meta‐analysis underscores ctDNA as a potential predictor of worse survival in patients with mUM, highlighting its potential to refine risk stratification and guide treatment strategies.Trial Registration: International Prospective Register of Systematic Reviews (PROSPERO): CRD42025638076
- 13 August 2025
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 38 (5) , e70047
Open AccessPrognostic and Predictive Value of ctDNA for Metastatic Uveal Melanoma: A Systematic Review and Meta‐Analysis
Metastatic uveal melanoma (mUM) is a rare disease associated with poor prognosis and limited therapeutic options. Recent studies showed that detecting ctDNA is feasible and can aid treatment decisions for patients with mUM. We systematically searched PubMed, EMBASE, and Cochrane databases for eligible studies published up to May 2025 that included patients with mUM and reported data on the association between ctDNA and survival outcomes (OS and PFS). Statistical analyses were performed using Review Manager 5.4 software. Of the initial 450 records, seven studies met eligibility, including 518 patients with mUM. At baseline, ctDNA positivity was associated with significantly worse PFS (HR 2.34; 95% CI 1.56–3.51; p < 0.01; I2 = 0%) and OS (HR 3.32; 95% CI 2.09–5.29; p < 0.01; I2 = 48%). In patients treated with tebentafusp, ctDNA clearance was associated with superior OS (HR 0.19; 95% CI 0.07–0.49; p < 0.01; I2 = 46%) and any decrease in ctDNA was associated with better OS (HR 0.42; 95% CI 0.22–0.80; p < 0.01; I2 = 0%). This meta‐analysis underscores ctDNA as a potential predictor of worse survival in patients with mUM, highlighting its potential to refine risk stratification and guide treatment strategies.Trial Registration: International Prospective Register of Systematic Reviews (PROSPERO): CRD42025638076
- 29 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (5) , 1911-1924
Is it Safe to Perform Concomitant Cholecystectomy in Patients With Confirmed Gallbladder Disease Undergoing Metabolic and Bariatric Surgery? An Updated Meta-Analysis
Introduction Obesity is a global public health issue, and metabolic and bariatric surgery (MBS) remains most effective intervention for achieving and maintaining long-term weight loss. However, rapid weight loss following MBS increases the risk of gallstone formation. Concomitant cholecystectomy (CC) during MBS has been proposed to mitigate this risk, but recent studies present conflicting evidence regarding its safety and efficacy, leaving no clear consensus. Methods We conducted a meta-analysis by systematically searching MEDLINE, Cochrane Central, Embase, and ClinicalTrials.gov for studies comparing CC plus BS versus BS alone. Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Statistical analyses were performed with Review Manager v5.4 and RStudio v4.3.3. PROSPERO ID: CRD42023480360. Results We included 26 studies encompassing 656,830 patients with confirmed gallstones, among whom 34,409 (5.2%) underwent CC.The mean age was 41.5 years, and 79.2% were female. Patients undergoing CC + MBS had increased postoperative bleeding (OR 1.31; 95% CI 1.06–1.62; p = 0.01), wound complications (OR 1.61; 95% CI 1.34–1.95; p < 0.01), respiratory complications (OR 1.49; 95% CI 1.13–1.95; p < 0.01), and anastomotic complications (OR 1.86; 95% CI 1.28–2.70; p < 0.01). No significant differences in operation time, rates of postoperative mortality, length of hospital stay, and vein thrombosis were found between groups. Conclusion CC during MBS increases operative time and postoperative complications, though only anastomotic complications are clinically significant. Therefore, CC should be reserved for high-risk or symptomatic patients and avoided in bariatric procedures involving an anastomosis due to the elevated risk of complications. Graphical Abstract
- 29 March 2025
- Published by Springer Nature in Obesity Surgery
- Vol. 35 (5) , 1911-1924
Is it Safe to Perform Concomitant Cholecystectomy in Patients With Confirmed Gallbladder Disease Undergoing Metabolic and Bariatric Surgery? An Updated Meta-Analysis
Introduction Obesity is a global public health issue, and metabolic and bariatric surgery (MBS) remains most effective intervention for achieving and maintaining long-term weight loss. However, rapid weight loss following MBS increases the risk of gallstone formation. Concomitant cholecystectomy (CC) during MBS has been proposed to mitigate this risk, but recent studies present conflicting evidence regarding its safety and efficacy, leaving no clear consensus. Methods We conducted a meta-analysis by systematically searching MEDLINE, Cochrane Central, Embase, and ClinicalTrials.gov for studies comparing CC plus BS versus BS alone. Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs) were pooled using a random-effects model. Statistical analyses were performed with Review Manager v5.4 and RStudio v4.3.3. PROSPERO ID: CRD42023480360. Results We included 26 studies encompassing 656,830 patients with confirmed gallstones, among whom 34,409 (5.2%) underwent CC.The mean age was 41.5 years, and 79.2% were female. Patients undergoing CC + MBS had increased postoperative bleeding (OR 1.31; 95% CI 1.06–1.62; p = 0.01), wound complications (OR 1.61; 95% CI 1.34–1.95; p < 0.01), respiratory complications (OR 1.49; 95% CI 1.13–1.95; p < 0.01), and anastomotic complications (OR 1.86; 95% CI 1.28–2.70; p < 0.01). No significant differences in operation time, rates of postoperative mortality, length of hospital stay, and vein thrombosis were found between groups. Conclusion CC during MBS increases operative time and postoperative complications, though only anastomotic complications are clinically significant. Therefore, CC should be reserved for high-risk or symptomatic patients and avoided in bariatric procedures involving an anastomosis due to the elevated risk of complications. Graphical Abstract
- Open Access
- 9 January 2025
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 5
The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis
- 9 January 2025
- Published by Elsevier in EJC Paediatric Oncology
- Vol. 5
Open AccessThe safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis
- Open Access
- 2 September 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 8 (5)
QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Cyclin-dependent kinases (CDK) 4/6 inhibitors have significantly improved outcomes for patients with ER+/HER2− breast cancer. Nevertheless, they differ from each other in terms of chemical, biological, and pharmacological features, as well as toxicity profiles. We aim to determine whether QTc prolongation is caused by CDK4/6i in general or if it is associated with ribociclib only. We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing the prevalence of QTc prolongation as an adverse event in HR+ breast cancer patients treated with CDK4/6i vs those without CDK4/6i. We pooled relative risk (RR) and mean difference (MD) with 95% confidence interval (CI) for the binary endpoint of QT prolongation. We included 14 RCTs comprising 16 196 patients, of whom 8576 underwent therapy with CDK4/6i. An increased risk of QTc prolongation was associated with the use of CDK4/6i (RR = 2.35, 95% CI = 1.67 to 3.29, P < .001; I2 = 44%). Subgroup analyses revealed a significant increase in the QTc interval for the ribociclib and palbociclib cohorts. The ribociclib subgroup showed a relative risk of 3.12 (95% CI = 2.09 to 4.65, P < .001; I2 = 12%), whereas the palbociclib subgroup had a relative risk of 1.51 (95% CI = 1.05 to 2.15, P = .025; I2 = 0%). Palbociclib was associated with QTc prolongation; however, the relative risk for any grade QTc was quantitively twice with ribociclib. Furthermore, grade 3 QTc prolongations were observed exclusively with ribociclib. These results are important for guiding clinical decision-making and provide reassurance regarding the overall safety profile of this drug class.
- 2 September 2024
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 8 (5)
Open AccessQTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials
Cyclin-dependent kinases (CDK) 4/6 inhibitors have significantly improved outcomes for patients with ER+/HER2− breast cancer. Nevertheless, they differ from each other in terms of chemical, biological, and pharmacological features, as well as toxicity profiles. We aim to determine whether QTc prolongation is caused by CDK4/6i in general or if it is associated with ribociclib only. We systematically searched PubMed, Embase, and Cochrane Library for randomized controlled trials (RCTs) comparing the prevalence of QTc prolongation as an adverse event in HR+ breast cancer patients treated with CDK4/6i vs those without CDK4/6i. We pooled relative risk (RR) and mean difference (MD) with 95% confidence interval (CI) for the binary endpoint of QT prolongation. We included 14 RCTs comprising 16 196 patients, of whom 8576 underwent therapy with CDK4/6i. An increased risk of QTc prolongation was associated with the use of CDK4/6i (RR = 2.35, 95% CI = 1.67 to 3.29, P < .001; I2 = 44%). Subgroup analyses revealed a significant increase in the QTc interval for the ribociclib and palbociclib cohorts. The ribociclib subgroup showed a relative risk of 3.12 (95% CI = 2.09 to 4.65, P < .001; I2 = 12%), whereas the palbociclib subgroup had a relative risk of 1.51 (95% CI = 1.05 to 2.15, P = .025; I2 = 0%). Palbociclib was associated with QTc prolongation; however, the relative risk for any grade QTc was quantitively twice with ribociclib. Furthermore, grade 3 QTc prolongations were observed exclusively with ribociclib. These results are important for guiding clinical decision-making and provide reassurance regarding the overall safety profile of this drug class.
- 19 July 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (3) , 1058-1068
Laparoscopic Versus Open Pancreatoduodenectomy for Periampullary Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Purpose Laparoscopic pancreatoduodenectomy (LPD) has emerged as an alternative to open technique in treating periampullary tumors. However, the safety and efficacy of LPD compared to open pancreatoduodenectomy (OPD) remain unclear. Thus, we conducted an updated meta-analysis to evaluate the efficacy and safety of LPD versus OPD in patients with periampullary tumors, with a particular focus on the pancreatic ductal adenocarcinoma patient subgroup. Methods According to PRISMA guidelines, we searched PubMed, Embase, and Cochrane Library in December 2023 for randomized controlled trials (RCTs) that directly compare LPD versus OPD in patients with periampullary tumors. Endpoints and sensitive analysis were conducted for short-term endpoints. All statistical analysis was performed using R software version 4.3.1 with a random-effects model. Results Five RCTs yielding 1018 patients with periampullary tumors were included, of whom 511 (50.2%) were randomized to the LPD group. Total follow-up time was 90 days. LPD was associated with a longer operation time (MD 66.75; 95% CI 26.59 to 106.92; p = 0.001; I2 = 87%; Fig. 1A), lower intraoperative blood loss (MD − 124.05; 95% CI − 178.56 to − 69.53; p < 0.001; I2 = 86%; Fig. 1B), and shorter length of stay (MD − 1.37; 95% IC − 2.31 to − 0.43; p = 0.004; I2 = 14%; Fig. 1C) as compared with OPD. In terms of 90-day mortality rates and number of lymph nodes yield, no significant differences were found between both groups. Conclusion Our meta-analysis of RCTs suggests that LPD is an effective and safe alternative for patients with periampullary tumors, with lower intraoperative blood loss and shorter length of stay.
- 19 July 2024
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (3) , 1058-1068
Laparoscopic Versus Open Pancreatoduodenectomy for Periampullary Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Purpose Laparoscopic pancreatoduodenectomy (LPD) has emerged as an alternative to open technique in treating periampullary tumors. However, the safety and efficacy of LPD compared to open pancreatoduodenectomy (OPD) remain unclear. Thus, we conducted an updated meta-analysis to evaluate the efficacy and safety of LPD versus OPD in patients with periampullary tumors, with a particular focus on the pancreatic ductal adenocarcinoma patient subgroup. Methods According to PRISMA guidelines, we searched PubMed, Embase, and Cochrane Library in December 2023 for randomized controlled trials (RCTs) that directly compare LPD versus OPD in patients with periampullary tumors. Endpoints and sensitive analysis were conducted for short-term endpoints. All statistical analysis was performed using R software version 4.3.1 with a random-effects model. Results Five RCTs yielding 1018 patients with periampullary tumors were included, of whom 511 (50.2%) were randomized to the LPD group. Total follow-up time was 90 days. LPD was associated with a longer operation time (MD 66.75; 95% CI 26.59 to 106.92; p = 0.001; I2 = 87%; Fig. 1A), lower intraoperative blood loss (MD − 124.05; 95% CI − 178.56 to − 69.53; p < 0.001; I2 = 86%; Fig. 1B), and shorter length of stay (MD − 1.37; 95% IC − 2.31 to − 0.43; p = 0.004; I2 = 14%; Fig. 1C) as compared with OPD. In terms of 90-day mortality rates and number of lymph nodes yield, no significant differences were found between both groups. Conclusion Our meta-analysis of RCTs suggests that LPD is an effective and safe alternative for patients with periampullary tumors, with lower intraoperative blood loss and shorter length of stay.